EMEA-000353-PIP02-16

Key facts

Active substance
Maribavir
Therapeutic area
Infectious diseases
Decision number
P/0315/2017
PIP number
EMEA-000353-PIP02-16
Pharmaceutical form(s)
  • Tablet
  • Tablet for oral suspension
  • Powder for oral suspension
Condition(s) / indication(s)
Treatment of cytomegalovirus (CMV) infection
Route(s) of administration
  • Oral use
  • Gastroenteral use
Contact for public enquiries
Shire Pharmaceuticals Ireland Limited

Tel. +800 6683 8470
E-mail: medinfoEMEA@shire.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating